BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 31142314)

  • 1. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.
    Snyder L; Neely ML; Hellkamp AS; O'Brien E; de Andrade J; Conoscenti CS; Leonard T; Bender S; Gulati M; Culver DA; Kaner RJ; Palmer S; Kim HJ;
    Respir Res; 2019 May; 20(1):105. PubMed ID: 31142314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry.
    Case AH; Hellkamp AS; Neely ML; Bender S; Dilling DF; Gulati M; Hotchkin DL; Huie TJ; Lancaster L; Snyder LD; Conoscenti CS; Palmer SM
    Ann Am Thorac Soc; 2020 Jun; 17(6):699-705. PubMed ID: 32040340
    [No Abstract]   [Full Text] [Related]  

  • 3. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry.
    Swaminathan AC; Hellkamp AS; Neely ML; Bender S; Paoletti L; White ES; Palmer SM; Whelan TPM; Dilling DF;
    Ann Am Thorac Soc; 2022 Jun; 19(6):981-990. PubMed ID: 35073248
    [No Abstract]   [Full Text] [Related]  

  • 4. Lung function trajectories in patients with idiopathic pulmonary fibrosis.
    Neely ML; Hellkamp AS; Bender S; Todd JL; Liesching T; Luckhardt TR; Oldham JM; Raj R; White ES; Palmer SM
    Respir Res; 2023 Aug; 24(1):209. PubMed ID: 37612608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
    Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
    Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalizations in patients with idiopathic pulmonary fibrosis.
    Kim HJ; Snyder LD; Adegunsoye A; Neely ML; Bender S; White ES; Conoscenti CS; Strek ME;
    Respir Res; 2021 Sep; 22(1):257. PubMed ID: 34592998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.
    Todd JL; Neely ML; Overton R; Durham K; Gulati M; Huang H; Roman J; Newby LK; Flaherty KR; Vinisko R; Liu Y; Roy J; Schmid R; Strobel B; Hesslinger C; Leonard TB; Noth I; Belperio JA; Palmer SM;
    Respir Res; 2019 Oct; 20(1):227. PubMed ID: 31640794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.
    de Andrade JA; Kulkarni T; Neely ML; Hellkamp AS; Case AH; Culver DA; Guntupalli K; Bender S; Conoscenti CS; Snyder LD;
    Respir Res; 2022 Jan; 23(1):3. PubMed ID: 34996465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry.
    O'Brien EC; Hellkamp AS; Neely ML; Swaminathan A; Bender S; Snyder LD; Culver DA; Conoscenti CS; Todd JL; Palmer SM; Leonard TB;
    Chest; 2020 May; 157(5):1188-1198. PubMed ID: 31954102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry.
    Snyder LD; Mosher C; Holtze CH; Lancaster LH; Flaherty KR; Noth I; Neely ML; Hellkamp AS; Bender S; Conoscenti CS; de Andrade JA; Whelan TP
    BMJ Open Respir Res; 2020 Jul; 7(1):. PubMed ID: 32624493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.
    Gao J; Kalafatis D; Carlson L; Pesonen IHA; Li CX; Wheelock Å; Magnusson JM; Sköld CM
    Respir Res; 2021 Feb; 22(1):40. PubMed ID: 33546682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
    Doubková M; Švancara J; Svoboda M; Šterclová M; Bartoš V; Plačková M; Lacina L; Žurková M; Binková I; Bittenglová R; Lošťáková V; Merta Z; Šišková L; Tyl R; Lisá P; Šuldová H; Petřík F; Pšikalová J; Řihák V; Snížek T; Reiterer P; Homolka J; Musilová P; Lněnička J; Palúch P; Hrdina R; Králová R; Hortvíková H; Strenková J; Vašáková M
    Clin Respir J; 2018 Apr; 12(4):1526-1535. PubMed ID: 28862397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.
    Fan Y; Bender SD; Conoscenti CS; Davidson-Ray L; Cowper PA; Palmer SM; de Andrade JA;
    Chest; 2020 Jun; 157(6):1522-1530. PubMed ID: 32004554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry.
    Kreuter M; Swigris J; Pittrow D; Geier S; Klotsche J; Prasse A; Wirtz H; Koschel D; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Held M; Bahmer T; Oqueka T; Frankenberger M; Behr J
    Respir Res; 2019 Mar; 20(1):59. PubMed ID: 30876420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis after lung transplantation: an analysis of the United Network of Organ Sharing registry.
    Hayes D; Higgins RS; Black SM; Wehr AM; Lehman AM; Kirkby S; Whitson BA
    J Heart Lung Transplant; 2015 Mar; 34(3):430-7. PubMed ID: 25444371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity.
    Serajeddini H; Rogliani P; Mura M
    Lung; 2018 Dec; 196(6):707-713. PubMed ID: 30151723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry.
    Salisbury ML; Conoscenti CS; Culver DA; Yow E; Neely ML; Bender S; Hartmann N; Palmer SM; Leonard TB;
    Ann Am Thorac Soc; 2020 Nov; 17(11):1413-1423. PubMed ID: 32574517
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple breath washout: A new and promising lung function test for patients with idiopathic pulmonary fibrosis.
    Nyilas S; Schreder T; Singer F; Poellinger A; Geiser TK; Latzin P; Funke M
    Respirology; 2018 Aug; 23(8):764-770. PubMed ID: 29573509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
    Jo HE; Glaspole I; Grainge C; Goh N; Hopkins PM; Moodley Y; Reynolds PN; Chapman S; Walters EH; Zappala C; Allan H; Keir GJ; Hayen A; Cooper WA; Mahar AM; Ellis S; Macansh S; Corte TJ
    Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28232409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.